ArticleCureus2025
Primary Cutaneous Epstein-Barr Virus (EBV)-Positive Diffuse Large B-cell Lymphoma With Synchronous Systemic T-cell Lymphoma: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) is a rare and aggressive lymphoma that has been associated with age-related immunosenescence. Here, we present the case of a 79-year-old man with violaceous nodules on the skin, mainly on the lower and upper limbs, diagnosed as primary cutaneous EBV-positive diffuse large B-cell lymphoma (DLBCL) based on histopathological and immunohistochemical findings. Systemic evaluation revealed synchronous peripheral T-cell lymphoma, not otherwise specified (NOS), without systemic B-cell lymphoma involvement. The patient was treated with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine (Oncovin), and prednisone (R-CHOP) chemotherapy, achieving a complete response for both lymphomas, with sustained outcomes after one year of follow-up. This case highlights the importance of age as a risk factor for EBV-related malignancies, the role of Epstein-Barr encoding region (EBER) and cluster of differentiation 30 (CD30) testing in diagnosis, and the potential effectiveness of R-CHOP in treating this rare lymphoma association. Further research is needed to establish optimal management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.